Renal Cell Carcinoma

Dr Daniel J. George Discusses the Use of Biomarkers in RCC Treatment

While there are reliable biomarkers to monitor disease progression and guide treatment decisions for tyrosine kinase inhibitors in renal cell carcinoma (RCC), there is a need for biomarkers for immunotherapies.

Site of Metastasis Is Significant in Renal Cell Carcinoma, Dr Daniel George Explains

Where renal cell carcinoma spreads can have a significant impact on prognosis and treatment options for patients.

Dr Rana McKay on First-Line Therapies for Metastatic Renal Cell Carcinoma

Dr Rana McKay on Second-Line Treatment Options for Advanced RCC

Dr Alan Tan on the Options for Patients With Advanced RCC

Survival is good for patients when renal cell carcinoma (RCC) is caught early, but options for advanced disease present challenges, explained Alan Tan, MD, an assistant professor in the Division of Hematology, Oncology and Cell Therapy at Rush Medical College and the director of GU Medical Oncology.

Dr Alan Tan Provides Overview of RCC Prevalence, Presentation, Diagnosis

Many times, renal cell carcinoma (RCC) is found incidentally, as a result of something else, said Alan Tan, MD, an assistant professor in the Division of Hematology, Oncology and Cell Therapy at Rush Medical College and the director of GU Medical Oncology.